Increasing pneumococcal vaccination for immunosuppressed patients: A cluster quality improvement trial

Brigham & Women's Hospital, Department of Medicine, Divisions of Rheumatology, Immunology, and Allergy. .
Arthritis & Rheumatology (Impact Factor: 7.87). 01/2013; 65(1). DOI: 10.1002/art.37716
Source: PubMed

ABSTRACT OBJECTIVE: Pneumoccocal vaccination is important for patients on immunosuppressive medications, but prior studies suggest that most patients do not undergo vaccination. We evaluated the effects of a point-of-care paper reminder form on being up-to-date with pneumococcal vaccination in a rheumatology practice. METHODS: Selected rheumatologists at five ambulatory practice sites received a point-of-care paper reminder form for patients who were not up-to-date with pneumococcal vaccination. Interrupted time-series analyses were used to measure the effect of the paper reminder form upon the intervention rheumatologists compared to the control rheumatologists. Adjusted Cox proportional hazards models were examined to identify independent predictors of being up-to-date with pneumococcal vaccination. RESULTS: We evaluated a total of 3,717 patients on immunosuppressive medications with 74.1% female, mean age of 53.7 years and 66.0% with rheumatoid arthritis. Rheumatologists who received the intervention had a significant increase in the rate of patients up-to-date with pneumococcal vaccination from 67.6% to 80.0% in the time period following the intervention (p=0.006), compared to control rheumatologists 52.3% to 52.0% (p=0.90). In regression models, the intervention [hazard ratio, HR=3.58, (95% CI 2.46-5.20)], having aprimary care physician affiliated with our hospital [HR=1.68, (95% CI 1.44-1.97)], diabetes mellitus [HR =1.57, (95% CI 1.02-2.41)] and patient age 56-65 years compared to age ≤ 45 years [HR=1.24, (95% CI 1.01-1.51)] were positive predictors of being up-to-date with vaccination. CONCLUSION: A simple point-of-care paper reminder for patients on immunosuppressive medications significantly increased the rate of being up-to-date with pneumococcal vaccination among intervention rheumatologists over a six-month period. © 2012 American College of Rheumatology.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with rheumatoid arthritis (RA) suffer an increased burden of infectious disease-related morbidity and mortality and have twice the risk of acquiring a severe infection compared to the general population. This increased risk is not only a result of the autoimmune disease but is also attributed to the immunosuppressive therapies that are commonly used in this patient population. Given the increase in infection-related risks in RA, there is great interest in mitigating such risk. A number of vaccines are available to the rheumatologist, with a handful that are of importance for RA patients in the United States. The goal of this paper is to highlight the most recent literature on the key vaccines and the specific considerations for the rheumatologist and their RA patients, with a particular focus on influenza, pneumococcal, and herpes zoster vaccines. It is important for rheumatologist to understand and be aware of which vaccines are live and what potential contraindications exist for giving vaccines to RA patients.
    Current Rheumatology Reports 08/2014; 16(8):431. DOI:10.1007/s11926-014-0431-x · 2.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunization is one of the most efficient preventive action. Health authorities are convinced of this priority, as it is shown in the recent recommandations. Nevertheless, the vaccine coverage rate is low, particularly in France. The pneumococcal vaccine is taken as an analysis to explain barriers and opportunities for immunization.
    06/2014; DOI:10.1016/j.antinf.2014.01.007
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pediatric patients with cancer face more severe complications of influenza than healthy children. Although Centers for Disease Control and Prevention guidelines recommend yearly vaccination in these patients, in our large academic center, <60% of oncology patients receiving chemotherapy were immunized at baseline. Our objective was to increase this rate through a multifaceted quality improvement initiative. Eligible patients were >6 months old, within 1 year of receiving chemotherapy, >100 days from stem cell transplant, and had ≥1 outpatient oncology visit between September 1, 2012, and March 31, 2013. Five interventions were instituted concomitantly: (1) family education: influenza/vaccine handouts were provided to families in clinic waiting rooms; (2) health informatics: daily lists of outpatients due for immunization were generated from the electronic medical record and sent automatically to triage staff and nurses; (3) outpatient clinic: patients due for vaccination were given colored wristbands during triage to alert providers; (4) inpatient: vaccine order was built into admission order set; and (5) provider education: staff education was provided at conferences on screening of patients, vaccine ordering, and documentation of refusals/contraindications. The complete influenza immunization rate increased by 20.1% to 64.5%, and the proportion of patients receiving ≥1 dose of vaccination increased by 22.9% to 77.7%. Similar changes were noted across all cancer types, with highest rates of immunization in leukemia/lymphoma patients (86.8%) and lowest in patients after stem cell transplant (66.7%). Technology, education, and multidisciplinary clinical process changes increased influenza vaccination rates. Ongoing efforts are targeting subgroups with lowest rates of immunization. Copyright © 2015 by the American Academy of Pediatrics.
    Pediatrics 01/2015; DOI:10.1542/peds.2014-0943 · 5.30 Impact Factor


1 Download